FDA gives expedited approval to new groundbreaking pancreatic cancer drug

The US Food and Drug Administration (FDA) recently granted expedited approval to a pioneering new drug called daraxonrasib for the treatment of pancreatic cancer, one of the deadliest types of cancer. Daraxonrasib is the first-of-its-kind pill that blocks a mutated protein responsible for fueling tumor growth in over 90% of pancreatic cancer cases.

The drug, sold under the brand name Rasonque by Revolution Medicines, was approved six months ahead of schedule, demonstrating the FDA's commitment to delivering more effective treatments to patients quickly.

In a clinical trial involving 500 patients with metastatic pancreatic cancer whose tumors had stopped responding to prior treatment, those who received daraxonrasib lived a median of 13.2 months compared to 6.7 months for those on chemotherapy. The daily pill has been shown to nearly double survival time with fewer severe side effects in patients.

Pancreatic cancer is notoriously difficult to detect early, as it often spreads to other organs before diagnosis. With about 67,000 new cases diagnosed annually in the United States and a five-year overall survival rate of just 13%, the drug has garnered significant public attention.

Former US Senator Ben Sasse of Nebraska experienced less pain from the treatment during a recent interview on CBS's 60 Minutes. The drug's success has sparked optimism among pancreatic cancer doctors, as dozens of experimental treatments are currently in development. Unlike other cancers that have benefited from a range of chemotherapy options, pancreatic cancer has been particularly challenging to treat due to the presence of Kras mutations, making the cancer cells highly resistant to traditional therapies.

Revolution Medicines' groundbreaking drug tackles this challenge by using a molecular glue to bind with multiple Kras subtypes, effectively targeting the root cause of pancreatic cancer growth.